{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-047835","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2022-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.204206+00:00","generated_at":"2026-06-26T06:14:31.760446+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"HOOKIPA board member Lengauer to depart; appoints Timothy Reilly as director","bullets":["Christoph Lengauer will not stand for re-election at June 30, 2022 annual meeting; departure not due to disagreement.","Timothy Reilly, Ph.D. appointed to board effective immediately; will serve as Class II director until 2024.","Reilly previously SVP at Bristol Myers Squibb, currently Chief Development Officer at HotSpot Therapeutics.","As non-employee director, Reilly receives initial option for 19,200 shares plus annual $40,000 cash retainer.","Reilly will join Nominating and Corporate Governance Committee on June 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-047835","json":"https://secwatch.observer/filing/0001104659-22-047835.json","markdown":"https://secwatch.observer/filing/0001104659-22-047835.md","text":"https://secwatch.observer/filing/0001104659-22-047835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922047835/0001104659-22-047835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922047835/tm2213066d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T06:14:31.760446+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15b7565721","claim":"Timothy Reilly was appointed as Director at HOOKIPA Pharma Inc..","evidence_excerpt":"On April 15, 2022, the Board appointed Timothy Reilly, Ph.D. as a director of the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922047835/0001104659-22-047835-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"96af5b13d5","claim":"Christoph Lengauer departed as Director at HOOKIPA Pharma Inc..","evidence_excerpt":"On April 15, 2022, Christoph Lengauer, a member of the board of directors (the “Board”) of HOOKIPA Pharma Inc. (the “Company”), notified the Company that he will not stand for re-election to the Board when his term expires at the Company’s 2022 annual meeting of shareholders on June 30, 2022 (the “2022 Annual Meeting”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922047835/0001104659-22-047835-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will not stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}